BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR...

July 01, 2026 | News

Innovent and Lilly Expand China Oncology Partnership with Verzenios Commercialisation Agreement

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

July 01, 2026 | News

NS Pharma Parent Nippon Shinyaku Secures Global Option Rights to Develop Elixirgen's DMD Therapy EXG-7001

NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon S...

June 30, 2026 | News

AbbVie Secures U.S. FDA Approval for SKYRIZI in Children with Plaque Psoriasis and Psoriatic Arthritis

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or activ...

June 30, 2026 | News

CStone Partners with Arrotex to Commercialize Sugemalimab in Australia and New Zealand

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration...

June 29, 2026 | News

Everest Medicines' LEROCHOL® BLA Accepted in China for Third-Generation PCSK9 Inhibitor

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

June 29, 2026 | News

The Frontier That Won’t Quite Arrive

Ask the region’s clinical-operations leaders whether decentralised and hybrid trials are the future, and the answer is almost unanimous. Surveys keep...

June 26, 2026 | Analysis

HKeyBio Launches NHP Fast-Tox Program to Accelerate Early Safety Assessment for Biologics

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics an...

June 26, 2026 | News

Abbisko Therapeutics Expands Strategic Alliance with Lilly in Multi-Target Drug Discovery Deal Worth Up to $1.9 Billion

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collab...

June 25, 2026 | News

Mabwell Secures China Clinical Trial Approval for First-in-Class LILRB4/CD3 Bispecific T-Cell Engager in Blood Cancers

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical P...

June 25, 2026 | News

WuXi Biologics Achieves First GMP Production at Shanghai MFG17, Expanding Global Biologics Manufacturing Capacity

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance f...

June 25, 2026 | News

ChemT Biotechnology Raises US$5 Million to Advance AI-Powered Biomanufacturing Platform

The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavem...

June 23, 2026 | News

Teijin Pharma Limited and Merz Therapeutics GmbH Win Japanese Approval for XEOMIN® in Cervical Dystonia and Blepharospasm

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurolog...

June 23, 2026 | News

Incyte Biosciences Japan Secures Japanese Approval for Minjuvi–Lenalidomide Combination in Relapsed/Refractory DLBCL

Incyte Biosciences Japan G.K. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab)...

June 23, 2026 | News

Stay Connected